Exelixis hits 25-year high after lifting 2025 revenue forecast

Shares of cancer drugmaker Exelixis EXEL.O rise as much as 19.2% to near 25-year high of $45.29

Stock is set for its best day in over five years, if gains hold

Co late on Tuesday raised 2025 rev. forecast between $2.25 billion and $2.35 billion, compared with prior view of between $2.15 billion and $2.25 billion

Co posted Q1 total rev. of $555.4 million, beating analysts' estimate of $498.2 million - data compiled by LSEG

Co posted Q1 adj. profit of 62 cents per share vs estimates of 36 cents per share on sales of its cancer drug, Cabometyx

Including session's moves, stock up 31.8% YTD